Literature DB >> 23398670

Which test to use to measure the anticoagulant effect of rivaroxaban: the anti-factor Xa assay.

M M Samama1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23398670     DOI： 10.1111/jth.12165

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  7 in total

1.  Unexpected Dynamic Binding May Rescue the Binding Affinity of Rivaroxaban in a Mutant of Coagulation Factor X.

Authors:  Zhi-Li Zhang; Changming Chen; Si-Ying Qu; Qiulan Ding; Qin Xu
Journal:  Front Mol Biosci       Date:  2022-05-05

2.  Management of bleeding associated with dabigatran and rivaroxaban: a survey of current practices.

Authors:  Lisa M Baumann Kreuziger; Mark T Reding
Journal:  Thromb Res       Date:  2013-07-31       Impact factor: 3.944

Review 3.  Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban.

Authors:  Wolfgang Mueck; Jan Stampfuss; Dagmar Kubitza; Michael Becka
Journal:  Clin Pharmacokinet       Date:  2014-01       Impact factor: 6.447

Review 4.  Coagulation assessment with the new generation of oral anticoagulants.

Authors:  Charles V Pollack
Journal:  Emerg Med J       Date:  2015-05-18       Impact factor: 2.740

5.  Accuracy of a Single, Heparin-Calibrated Anti-Xa Assay for the Measurement of Rivaroxaban, Apixaban, and Edoxaban Drug Concentrations: A Prospective Cross-Sectional Study.

Authors:  Tamana Meihandoest; Jan-Dirk Studt; Adriana Mendez; Lorenzo Alberio; Pierre Fontana; Walter A Wuillemin; Adrian Schmidt; Lukas Graf; Bernhard Gerber; Ursula Amstutz; Cedric Bovet; Thomas C Sauter; Lars M Asmis; Michael Nagler
Journal:  Front Cardiovasc Med       Date:  2022-03-17

6.  Simple and rapid assay for effect of the new oral anticoagulant (NOAC) rivaroxaban: preliminary results support further tests with all NOACs.

Authors:  Raul Altman; Claudio Daniel Gonzalez
Journal:  Thromb J       Date:  2014-03-21

7.  Laboratory Assessment of the Anticoagulant Activity of Apixaban in Patients With Nonvalvular Atrial Fibrillation.

Authors:  Elias Kyriakou; Konstantinos Katogiannis; Ignatios Ikonomidis; George Giallouros; Georgios K Nikolopoulos; Evdoxia Rapti; Maria Taichert; Katerina Pantavou; Argiri Gialeraki; Foteini Kousathana; Aristarchos Poulis; Andreas G Tsantes; Stefanos Bonovas; Violetta Kapsimali; Georgios Tsivgoulis; Argirios E Tsantes
Journal:  Clin Appl Thromb Hemost       Date:  2018-10-01       Impact factor: 2.389
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.